CytomX Therapeutics Reports Q4 Earnings Miss

Biopharmaceutical company posts lower-than-expected revenue and wider loss

Mar. 16, 2026 at 11:25am

Got story updates? Submit your updates here. ›

CytomX Therapeutics Inc., a biopharmaceutical company based in South San Francisco, California, reported a loss of $26.5 million in its fourth quarter, missing Wall Street expectations. The company's revenue of $663,000 also fell short of analyst forecasts.

Why it matters

CytomX Therapeutics is a prominent biopharmaceutical firm in the South San Francisco area, and its quarterly earnings are closely watched by investors and industry analysts as an indicator of the company's financial health and performance.

The details

On a per-share basis, CytomX reported a loss of 22 cents, compared to the average analyst estimate of a loss of 8 cents per share. The company's revenue of $663,000 also missed the $7.4 million expected by analysts surveyed by Zacks Investment Research. For the full year, CytomX reported a loss of $17.4 million, or 15 cents per share, on revenue of $76.2 million.

  • CytomX Therapeutics reported its Q4 2025 earnings on Monday, March 16, 2026.

The players

CytomX Therapeutics Inc.

A biopharmaceutical company based in South San Francisco, California that develops novel cancer therapies.

Got photos? Submit your photos here. ›

The takeaway

CytomX Therapeutics' Q4 earnings miss highlights the challenges the company faces in developing and commercializing new biopharmaceutical products, and investors will be closely watching the company's future performance and strategic initiatives.